Screening method for agents that modulate human NIK activity
AssigneeTularik Inc.
InventorsMike Rothe, Lin Wu
Life of this patent
Estimating the term…
Abstract
The invention provides methods and compositions relating to a novel kinase, NIK, involved in NF.kappa.B activation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed NIK encoding nucleic acids or purified from human cells. The invention provides isolated NIK hybridization probes and primers capable of specifically hybridizing with the disclosed NIK genes, NIK-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
Claims9
A method of screening for an agent which modulates the interaction of a nuclear factor-.kappa.B-inducing kinase (NIK) polypeptide with a NIK binding target, said method comprising the steps of:
- incubating a mixture comprising:
- an isolated polypeptide comprising at least 10 consecutive amino acid residues of the amino acid sequence set forth as SEQ ID NO:2, which consecutive amino acid residues comprise the amino acid residue 25 of SEQ ID NO:2,
- a binding target of said isolated polypeptide, and
- a candidate agent,
- under conditions whereby, but for the presence of said candidate agent, said isolated polypeptide specifically binds said binding target of said isolated polypeptide at a reference affinity and
- detecting the binding affinity of said isolated polypeptide to said binding target of said isolated polypeptide to determine an agent-biased affinity,
- wherein a difference between the agent-biased affinity and the reference affinity indicates that said candidate agent is an agent that modulates the interaction of said NIK polypeptide with said NIK binding target.
Dependencies are inferred from the claim text.